All In Biotech

Drug Trial Radar · NCT04676646

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

366

Actual

Start

Mar 8, 2021

Primary completion

Jul 15, 2024

Study completion Jul 15, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).

Conditions

  • Hyperkalaemia
  • Heart Failure With Reduced Ejection Fraction

Interventions

  • Sodium zirconium cyclosilicateDrug

    Investigational medicinal product

  • PlaceboDrug

    Placebo comparator

  • SpironolactoneOther

    Background intervention. During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for HyperkalaemiaTime frame: From Month 1 (Visit 9) to Month 6 (Visit 14), up to 6 months

Locations

89 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Fairhope, Alabama

  • Research Site

    Los Angeles, California

  • Research Site

    Torrance, California

  • Research Site

    Evanston, Illinois

  • Research Site

    Hazel Crest, Illinois

  • Research Site

    Oak Lawn, Illinois

  • Research Site

    Kansas City, Missouri

  • Research Site

    New York, New York

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Greenville, South Carolina

  • Research Site

    Houston, Texas

  • Research Site

    Falls Church, Virginia

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Bragança Paulista, Brazil

  • Research Site

    Brasília, Brazil

  • Research Site

    Brasília, Brazil

  • Research Site

    Campina Grande do Sul, Brazil

  • Research Site

    Campinas, Brazil

  • Research Site

    Canoas, Brazil

  • Research Site

    Joinville, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Santa Cruz do Sul, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Votuporanga, Brazil

  • Research Site

    Cambridge, Ontario, Canada

  • Research Site

    Kitchener, Ontario, Canada

  • Research Site

    Scarborough Village, Ontario, Canada

  • Research Site

    Scarborough Village, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Whitby, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.